Search

Advanced interventional pulmonology techniques are revolutionizing the diagnosis and treatment of lung cancer, often minimizing the need for multiple invasive procedures.

… Tuesday, January 16, 2018 Advanced interventional pulmonology (IP) techniques are revolutionizing the diagnosis and treatment of lung cancer. Minimally invasive bronchoscopy allows doctors with specialized training to accurately diagnose and stage lung cancer and to provide less-invasive therapeutic

先进的介入性肺脏病学技术正在彻底改变肺癌的诊断和治疗，通常尽量将多种侵入性手术的需求降至最低。

… Tuesday, January 16, 2018 先进的 介入性肺病学 (IP) 技术正在彻底改变肺癌的诊断和治疗。经专门培训的医生可以通过微创支气管镜检查准确诊断和分期肺癌，并为恶性气道、胸膜腔和肺实质疾病患者提供微创治疗和姑息治疗。 在 Memorial Sloan Kettering Cancer Center (MSK)， 自 2008 年与两位主治医师一起成立 IP 部门以来， 我们一直在介入性肺科学领域处于领先地位。( www.mskcc.org/IP )。我们的团队在肺癌患者症状管理循证临床实践指南的开发  (1) 、该领域医生培训考试的有效性  (2) ，以及最近用于癌症分期的超声引导下经支气管针吸活检术

Anthony Antonelli is an unlikely scientist. A “rambunctious” child, born in Queens and raised on Long Island, he was smart and creative — but not very keen on academics. “If it wasn’t a guitar or skateboard, I wasn’t interested,” he remembers.

… Friday, September 30, 2022 Anthony Antonelli Anthony Antonelli  is an unlikely scientist. A “rambunctious” child, born in Queens and raised on Long Island, he was smart and creative — but not very keen on academics. “If it wasn’t a guitar or skateboard, I wasn’t interested,” he remembers. Finding the

Memorial Sloan Kettering Cancer Center (MSK) today announced details of strategic real estate investments that will support the world class cancer center into the future. In March 2022, MSK announced plans to build a new, state-of-the-art cancer care Pavilion on the Upper East Side campus to address the evolving cancer care needs of patients over the next century.

… Monday, September 12, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced details of strategic real estate investments that will support the world class cancer center into the future. In March 2022, MSK announced plans to build a new, state-of-the-art cancer care Pavilion on the Upper East

September is Pediatric Cancer Awareness Month and at Memorial Sloan Kettering Cancer Center, we continue to work to bring awareness and advance research and treatments for our youngest and most vulnerable patients — not only in September, but every day.

… Wednesday, September 29, 2021 September is Pediatric Cancer Awareness Month and at Memorial Sloan Kettering Cancer Center, we work to bring awareness and advance research and treatments for our youngest and most vulnerable patients every day. To advance this cause, the 2021 Kids Walk for MSK Kids was

In this interview, hematologic oncologist Eytan Stein, Director of the Program for Drug Development in Leukemia, talks about the latest advances in treatment for AML and how people can benefit from receiving their treatment at MSK.

… Monday, November 18, 2024 Acute myeloid leukemia (AML) is one of the most common types of blood cancer. The word “acute” means that the cancer can advance quickly and needs to be treated right away. The word “myeloid” refers to the type of blood cells that are cancerous. Myeloid cells are blood cells

Eight scientists are poised to receive their doctorates and embark on careers tackling problems in human disease through biomedical research. Their years of dedication and training will be recognized on May 18, 2022, when they will be awarded their PhD degrees from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK). This year’s commencement marks the school’s 11th graduating class since admitting its first students in 2006.

… Monday, May 16, 2022 Eight scientists are poised to receive their doctorates and embark on careers tackling problems in human disease through biomedical research. Their years of dedication and training will be recognized on May 18, 2022, when they will be awarded their PhD degrees from the Gerstner Sloan

… Tuesday, September 3, 2024 Dear MSK Community, Our knowledge of cancer — what it is and how it progresses — has developed at a staggering pace over the past 20 years. Today, thanks to remarkable advances in the understanding of how cancer cells behave and evolve, many led by MSK, researchers have devised

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments:

… Wednesday, April 27, 2022 Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments: Jorge S. Reis-Filho Named a Susan G. Komen Scholar Jorge S. Reis-Filho Jorge S. Reis-Filho, MD, PhD, FRCPath, Chief, Experimental Pathology Service, was named a Susan G. Komen Scholar

Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ancestries, according to new MSK research. This trend could exacerbate disparities in cancer outcomes.

… Thursday, January 9, 2025 Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century have received that approval based on their ability to target genetic changes driving tumor growth. Medical oncologists use information about the genetic